The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-01. Anything still debated is marked as such rather than presented as settled.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R agonist | Subtype most often linked to behavioural effects |
| Other reported targets | MC1R, MC3R, MC5R | Activity is not selective for a single subtype |
| Endogenous ligand class | Melanocortin peptides | Alpha-MSH and ACTH act on the same family |
| Peptide architecture | Cyclic heptapeptide | Lactam bridge between the aspartate and lysine residues |
| Central action | Inferred from animal models | Not directly measured in the human brain |
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
== Overview == A sample large-scale phosphoproteomic analysis includes cultured cells undergo SILAC encoding; cells are stimulated with factor of interest (e.g. growth factor, hormone); stimulation can occur for various lengths of time for temporal analysis, cells are lysed and enzymatically digested, peptides are separated using ion exchange chromatography; phosphopeptides are enriched using phosphospecific antibodies, immobilized metal affinity chromatography or titanium dioxide (TiO2) chromatography; phosphopeptides are analyzed using mass spectrometry, and peptides are sequenced and analyzed.
== Corneal nerves == Corneal nerves serve as a form of defense by detecting the presence of foreign bodies on the corneal surface. This leads to reflexive reactions such as increased lacrimal secretion, blinking, and release of neuropeptides, which can induce cytokine activation.
high affinity towards the target (less than 1 μM) selectivity versus other targets significant efficacy in a cellular assay druglikeness (moderate molecular weight and lipophilicity usually estimated as ClogP). Affinity, molecular weight and lipophilicity can be linked in single parameter such as ligand efficiency and lipophilic efficiency. low to moderate binding to human serum albumin low interference with P450 enzymes and P-glycoproteins low cytotoxicity metabolic stability high cell membrane permeability sufficient water solubility (above 10 μM) chemical stability synthetic tractability patentability The project team will usually select between three and six compound series to be further explored. The next step will allow the testing of analogous compounds to determine a quantitative structure-activity relationship (QSAR). Analogs can be quickly selected from an internal library or purchased from commercially available sources ("SAR by catalog" or "SAR by purchase"). Medicinal chemists will also start synthesizing related compounds using different methods such as combinatorial chemistry, high-throughput chemistry, or more classical organic chemistry synthesis.
The Census Bureau's 2006–2010 American Community Survey showed that (in 2010 inflation-adjusted dollars) median household income was $105,625 (with a margin of error of +/− $14,945) and the median family income was $128,382 (+/− $16,732). Males had a median income of $95,795 (+/− $24,665) versus $72,188 (+/− $16,155) for females. The per capita income for the borough was $56,485 (+/− $6,202). About 2.4% of families and 4.0% of the population were below the poverty line, including 1.8% of those under age 18 and 9.4% of those age 65 or over.
Carnivora have a simple stomach adapted to digest primarily meat, as compared to the elaborate digestive systems of herbivorous animals, which are necessary to break down tough, complex plant fibers. The cecum is either absent or short and simple, and the large intestine is not sacculated or much wider than the small intestine.
Sources: en.wikipedia.org
=== Animal models === Gabapentin prevents seizures in a dose-related manner in several laboratory animal models. These models include spinal extensor seizures from low-intensity electroshock to the forebrain in mice, maximal electroshock in rats, spinal extensor seizures in DBA/2 mice with a genetic sensitivity to seizures induced by loud noise, and in rats "kindled" to produce focal seizures by repeated prior electrical stimulation of the hippocampus. Gabapentin slightly increased spontaneous absence-like seizures in a genetically susceptible strain recorded with electroencephalography. All of these effects of gabapentin were seen at dosages at or below the threshold for producing ataxia. Gabapentin has been tested in a variety of animal models relevant to analgesic actions. Generally, gabapentin is not active to prevent pain-related behaviors in models of acute nociceptive pain. It prevents pain-related behaviors when animals are made sensitive by prior peripheral inflammation or peripheral nerve damage (inflammatory or neuropathic conditions).
=== Expansions to 529 education cost plans === A 529 plan will be allowed to distribute funds for the cost to attend an elementary or secondary school, including a public, private, or religious school, after July 4, 2025. Eligible costs include tuition, curriculum and curricular materials, books, instructional materials, online educational materials, and tuition for certain tutoring or educational classes outside one's home. A 529 plan will be allowed to distribute funds for eligible costs of a state and federal licensing program, an industry certification program, or a registered apprenticeship program after July 4, 2025. Eligible costs include tuition, fees, books, supplies, required testing, and continuing education needed to maintain the credential.
Venturing beyond Cumana, Humboldt and Bonpland received hospitality from local mulatto peasants, who were unfamiliar with their European origins but generous nonetheless. During one such excursion, they learned of a local laborer named Francisco Loyano, who had reportedly nursed a child with his own milk due to unusual lactation, a fact confirmed by local witnesses and Bonpland’s examination. By early September, acclimatized and prepared, Humboldt and Bonpland embarked on their first significant inland journey to the Cumanagoto tribe missions in the mountains south of Cumana. The challenging route led them through dense rainforest, across mountain streams, and along precipitous paths, where they marveled at the forest’s grandeur and the diversity of wildlife. The mission headquarters at Caripe, a cool, spring-fed location surrounded by mountains, became their base. Humboldt was surprised to find the Capuchin monks welcoming and tolerant, despite religious differences, and noted the presence of contemporary scientific texts among them. Daily life at Caripe was a blend of scientific work and cultural observation. Humboldt and Bonpland collected plants, studied the Cumanagoto language, and documented local customs, including the children’s consumption of large millipedes. Meals at the monastery reflected the monks’ sacrifices, as they often gave up their own rations for the guests. The soundscape was dominated by howler monkeys, especially during rain, and opportunities for astronomical observation were rare due to persistent mist.
=== Fresno mold and ropiness === In the mid-20th century, a cottony mycelium-like growth began appearing in the bottles of some sweet fortified wines produced in California's Central Valley. Being fortified, these wines often had alcohol levels in excess of 20% which is usually a level that discourages growth of most spoilage organisms associated with winemaking. Nicknamed "Fresno mold" due to where it was first discovered, the culprit of this growth was determined to be L. fructivorans, a species which can be controlled by sanitation and maintaining adequate sulfur dioxide levels. Some Lactobacillus and Pediococcus species (particularly P. damnosus and P. pentosaceus) have the potential to synthesize polysaccharides that add an oily viscosity to the wine. In the case of Lactobacillus, some of these saccharides may be glucans that can be synthesized from glucose present in the wine as low as 50–100 mg/L (0.005 to 0.01% residual sugar) and afflict seemingly "dry" wines. While "ropiness" can occur in the barrel or tank, it is often observed in the wines several months after they are bottled. Wines with pH levels above 3.5 and low sulfur dioxide levels are at most risk for developing this fault. Called graisse (or "grease") by the French and les vins filant by Pasteur, this fault has been observed in apple wines and cider. It can also be potentially be caused by other spoilage microbes such as Streptococcus mucilaginous, Candida krusei, and Acetobacter rancens.
Sources: en.wikipedia.org
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.
It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.
Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.